CACNA1A and non-small cell lung carcinoma: In combination treatment KRT232 plus navitoclax in NSCLC, controlling FDR at 0.1, resulting in 136, 150, and 145 pathways were significantly associated with HSA, RA, and BI, respectively, with 118 intersecting pathways across the three reference models (Fig. 3a).